Quest for African AIDS Vaccine Hampered by Focus, Virus Mutation

Important note: Information in this article was accurate in 2001. The state of the art may have changed since the publication date.

Quest for African AIDS Vaccine Hampered by Focus, Virus Mutation

Agence France Presse (12.13.01) - Thursday, December 13, 2001
Richard Ingham

Researchers in Burkina Faso at the conference on AIDS in Africa heard evidence that the search for a vaccine to fight HIV on the continent is being clouded by a focus on viral sub- types predominant in the West and by the virus' ability to mutate.

Two-thirds of the world's 40 million HIV-positive people live in sub-Saharan Africa. The predominant sub-types of HIV-1 - by far the most prevalent and vicious of the two known major strains of the virus -are A in eastern Africa; C in southern Africa and the Horn of Africa; and mixed A/G in western and central Africa. But of the vaccines in trials today, 70 percent are modeled on the genetic profile of sub-type B, which predominates among HIV patients in the United States. Only 3 percent address the sub-types of the African epidemic. "HIV vaccines should be designed for effectiveness in sub- Saharan Africa," said Harvard University vaccine expert Max Essex. "Any vaccine that works must be made available first, or concurrently, in sub-Saharan Africa."

"The truth is that we do not know whether a vaccine designed for one kind of sub-types will work on another, or if so what its effectiveness will be," said Eric Delaporte, a virologist at France's Research Institute for Development. "In vitro, it appears to work, but there has been no confirmation in vivo, and of course we still do not know about the results on humans." Only one candidate vaccine, gp120 (AIDSVAX), has made it to Phase III trials.

Adding to the problem is the remarkable ability of viral sub- types to swap genes, fueling fear that HIV could become a moving target for vaccine engineers. "Recombinant viruses contribute to 10-30 percent of the global pandemic," said Soleymane M'Boup of Senegal, the discoverer of HIV-2. "The frequency of subtypes will increase." Delaporte said that once an effective vaccine is found, it should be possible to deal with new recombinants in the same way scientists tweak flu vaccines to deal with new sub-strains. "But this requires good epidemiological infrastructure," he said, which means tracking newly emerging recombinant strains.
011213
AD012160

Copyright © 2001 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.

Always watch for outdated information. This article first appeared in 2001. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2001. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.